Psycho—pharmacologia

Volume 46 1976

Managing Editors H. Barry III J. O. Cole M. Hamilton E. Jacobsen R. W. Russell

Editorial Board

H. Barry III, Pittsburgh
D. Bovet, Roma
J. O. Cole, Boston
J. Delay, Paris
J. Elkes, Baltimore
M. Hamilton, Leeds
H. Isbell, Lexington
E. Jacobsen, København
M. E. Jarvik, Los Angeles
S. S. Kety, Boston
C. Kornetsky, Boston
R. W. Russell, Bedford Park
M. Shepherd, London
Hannah Steinberg, London
E. Strömgren, Risskov
A. Wikler, Lexington

Supporting Editors

M. Adler, Philadelphia
N.-E. Andén, Göteborg
J. Angst, Zürich
J. B. Appel, Columbia, SC
S. Barondes, La Jolla
A. M. Barrett, Leeds
H. Blaschko, Oxford
D. Booth, Birmingham
H. Brill, New York
P. L. Carlton, New Brunswick
C. K. Connors, Boston
P. B. Dews, Boston
A. DiMascio, Boston
E. Domino, Ann Arbor
J. C. Eccles, Buffalo
U. S. von Euler, Stockholm
A. Fessard, Paris
M. Fink, New York
S. Fisher, Boston
R. Fog, Roskilde
S. Garattini, Milano
S. Gershon, New York
S. C. Goldberg, Chevy Chase
S. P. Grossman, Chicago
L.-M. Gunne, Uppsala
H. Hanson, West Point
J. Harvey, Iowa City
H. E. Hill, Lexington
R. Hind, Cambridge
H. Hippius, München
L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto
E. Hosoya, Tokyo
R. P. Hullin, Leeds
S. Irwin, Portland
L. L. Iversen, Cambridge
J. Jaffe, Chicago
W. Janke, Düsseldorf
R. Jewett, Atlanta
R. T. Jones, San Francisco
M. Jouvet, Lyon
C. R. B. Joyce, Basel
D. Joyce, Perpignan
M. Katz, Rockville
R. Kelleher, Boston
K. F. Killam, Davis
G. Klerman, Boston
N. S. Kline, Orangeburg
M. H. Lader, London
I. P. Lapin, Leningrad
L. Lasagna, Rochester
V. G. Laties, Rochester
A. Latz, Boston
O. Lingjærde, Tromsø
R. Lipman, Rockville
A. Lubin, San Diego
E. Marley, London
W. R. Martin, Lexington
J. L. McGaugh, Irvine
D. E. McMillan, Chapel Hill
N. Mello, Washington
A. F. Mirsky, Boston
C. Niemegeers, Beerse
S. Norton, Kansas City
D. H. Overstreet, Bedford Park
D. Overton, Philadelphia
G. Pampiglione, London
P. Pichot, Paris
R. W. Pickens, Minneapolis
A. Randrup, Roskilde
D. Richter, Epsom
K. Rickels, Philadelphia
R. Rodnight, London
J. T. Rose, Leeds
R. T. Rubin, Los Angeles
M. Sandler, London
J. Scheel-Krüger, Roskilde
J. Schildkraut, Boston
C. Schuster, Chicago
R. Shader, Newton Centre, MA
C. Shagass, Philadelphia
P. Silverman, Macclesfield
F. Sjöqvist, Stockholm
J. R. Smythies, Edinburgh
F. Sulser, Nashville
R. Taber, Bloomfield
J. Tecce, Boston
T. Thompson, Minneapolis
S. Udenfriend, Nutley, NJ
H. Weil-Malherbe, Washington
A. Weissman, Groton, CT
T. Yanagita, Kawasaki
E. Zaimis, London
O. Zangwill, Cambridge

Springer-Verlag Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin · Heidelberg · New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag Berlin · Heidelberg 1976

Contents

Ageel, A. M., Chin, L., Trafton, C. L., Jones, B. C., Picchioni, A. L.
Acute Effects of Morphine and Chlorpromazine on the Acquisition of Shuttle Box Conditioned Avoidance Response 311

Arai, E., see Kobayashi, M. 317

Asper, H., see Ruch, W., et al. 103

Ayhan, H., see Papeschi, R., et al. 149

Balster, R. L., Kilbey, M. M., Ellinwood, Jr., E. H.
Metamphetamine Self-Administration in the Cat 229

Barrett, R. J., see Leith, N. J. 19

Beautrais, A. L., Marks, D. F.
A Test of State Dependency Effects in Marihuana Intoxication for the Learning of Psychomotor Tasks 37

Beecher, M. D., Jackson, D. E.
Rate-Dependent Effect of Amphetamine in Rats: Extension to Between-Subject Effect 307

Benešová, O., see Tikal, K., et al. 325

Bergande, F., see Stock, G., et al. 197

Bergmann, F., Chaimovitz, M., Pasternak, V.
Dual Action of Morphine and Related Drugs on Compulsive Gnawing of Rats 87

Bernasconi, S., see Samanin, R., et al. 219

Bigler, E. D., Fleming, D. E.
Pharmacological Suppression of Photically Evoked After-Discharges in Rats: Incremental Dose, Hippocampal EEG and Behavioral Activity Correlates 73

Bläsig, J., Höllt, V., Herz, A., Paschelke, G.
Comparison of Withdrawal Precipitating Properties of Various Morphine Antagonists and Partial Agonists in Relation to Their Stereospecific Binding to Brain Homogenates 41

Bläsig, J., see Laschka, E., et al. 133

Bond, N. W., Di Giusto, E. L.
Effects of Prenatal Alcohol Consumption on Open-Field Behaviour and Alcohol Preference in Rats 163

Brown, C. P., see Stanes, M. D., et al. 269

Bueno, O. F. A., Carlini, E. A., Finkelfarb, E., Suzuki, J. S.
Δ^9-Tetrahydrocannabinol, Etanol, and Amphetamine as Discriminative Stimuli-Generalization Tests with Other Drugs 235

Bürki, H. R., see Ruch, W., et al. 103

Bureš, J., see Burešová, O. 93

Burešová, O., Bureš, J.
Piracetam-Induced Facilitation of Interhemispheric Transfer of Visual Information in Rats 93

Carlini, E. A., see Bueno, O. F. A., et al. 235

Carlini, E. A., see Fonseca, N. M., et al. 263

Carlson, R. H., see Schreiber, H. L., et al. 111

Cerkin, A., see Riege, W. H. 31

Chaimovitz, M., see Bergmann, F., et al. 87

Chesher, G. B., see Welburn, P. J., et al. 83

Chin, L., see Ageel, A. M., et al. 311

Collins, A. C., see Sanders, B., et al. 159

Colpaert, F. C., Niemegeers, C. J. E., Janssen, P. A. J.
Theoretical and Methodological Considerations on Drug Discrimination Learning 169

Di Giusto, E. L., see Bond, N. W. 163

Driscoll, P.
Nicotine-Like Behavioral Effect after Small Dose of Mecamylamine in Roman High-Avoidance Rats 119

Dunner, D. L., see Levitt, M., et al. 205

Ellinwood, E. H., Jr., see Balster, R. L., et al. 229

Fieve, R. R., see Levitt, M., et al. 205

Finkelfarb, E., see Bueno, O. F. A., et al. 235

Fjerdingstad, E., see Tetsche, K., et al. 123

Fjerdingstad, E. J., see Tetsche, K., et al. 123

Fleiss, J. L., see Levitt, M., et al. 205

Fleming, D. E., see Bigler, E. D. 73

Fonseca, N. M., Sell, A. B., Carlini, E. A.
Differential Behavioral Responses of Male and Female Adult Rats Treated with Five Psychotropic Drugs in the Neonatal Stage 263

Fraňková, S., see Tikal, K., et al. 325

Frewin, D. B., see Levitt, M., et al. 205

Frumkin, K.
Differential Potency of Taste and Audiovisual Stimuli in the Conditioning of Morphine Withdrawal in Rats 245

Gerald, M. C., Richter, N. A.
Studies on the Effect of Histaminergic Agents on Seizure Susceptibility in Mice 277

Gillies, R., see Noble, E. P., et al. 127

Ginsburg, B. E., see Yanai, J. 185

Gispen, W. H., see de Wied, D. 27

Gomeni, R., see Morselli, P. L., et al. 211

Grant, L. D., see Jones, C. N., et al. 59

Guazelli, M., see Morselli, P. L., et al. 211

Hance, A. J., see Ts'o, T. O. T., et al. 65

Heer-Carcano, L., see Waser, P. G., et al. 249

Heinemann, H., see Stock, G., et al. 197

Herz, A., see Bläsig, J., et al. 41

Herz, A., see Laschka, E., et al. 133, 141

Höllt, V., see Bläsig, J., et al. 41

Holtzman, S. G.
Comparison of the Effects of Morphine, Pentazocine, Cyclazocine and Amphetamine on Intracranial Self-Stimulation in the Rat 223

Jackson, D. E., see Beecher, M. D. 307

Jackson, D. M., see Welburn, P. J., et al. 83

Jahn, U., Mixich, G.
Benzylidenaminooxy-Carbonsäure-Derivate als Auslöser von "Wet Dog Shake"-Verhalten bei normalen Ratten 191

Janssen, P. A. J., see Colpaert, F. C., et al. 169

Johnstone, E. C.
The Relationship between Acetylator Status and Inhibition of Monoamine Oxidase, Excretion of Free Drug and Antidepressant Response in Depressed Patients on Phenelzine 289

Jones, B. C., see Ageel, A. M., et al. 311

Jones, C. N., Grant, L. D., Vospalek, D. M.
Temporal Parameters of *d*-Amphetamine as a Discriminative Stimulus in the Rat 59

Kakihana, R., Moore, J. A.
Circadian Rhythm of Corticosterone in Mice: The Effect of Chronic Consumption of Alcohol 301

Kilbey, M. M., see Balster, R. L., et al. 229

Killam, K. F., see Ts'o, T. O. T., et al. 65

Koboyashi, M., Arai, E.
Effect of Cortisone, Aldosterone and Nialamide on "Amphetamine Stereotypies" and Brain Methamphetamine Levels of Adrenalectomized Rats 317

Korr, H.
Autoradiographic Studies on the Distribution of ^{3}H-Mescaline in the Brain of the Marmoset, *Callithrix jacchus* 115

Korr, H., Seiler, N.
Autoradiographic Studies on the Distribution of ^{3}H-2,3,4-Trimethoxy-β-phenylethylamine in the Mouse 53

Laschka, E., Herz, A., Bläsig, J.
Sites of Action of Morphine Involved in the Development of Physical Dependence in Rats. I. Comparison of Precipitated Morphine Withdrawal after Intraperitoneal and Intraventricular Injection of Morphine Antagonists 133

Laschka, E., Teschemacher, rlj., Mehraein, P., Herz, A.
Sites of Action of Morphine Involved in the Development of Physical Dependence in Rats. II. Morphine Withdrawal Precipitated by Application of Morphine Antagonists into Restricted Parts of the Ventricular System and by Microinjection into Various Brain Areas 141

Lawlor, W., see Levitt, M., et al. 205

Leith, N. J., Barrett, R. J.
Amphetamine and the Reward System: Evidence for Tolerance and Post-Drug Depression 19

Leonard, B. E.
Acute and Chronic Effects of 4-Chloroamphetamine on Monoamine Metabolism in the Rat Brain 11

Levitt, M., Dunner, D. L., Mendlewicz, J., Frewin, D. B., Lawlor, W., Fleiss, J. L., Stallone, F., Fieve, R. R.
Plasmo Dopamine β Hydroxylase Activity in Affective Disorders 205

de Lisio, G., see Morselli, P. L., et al. 211

Maggini, C., see Morselli, P. L., et al. 211

Mandel, P., see Noble, E. P., et al. 127

Markomihelakis, H., see Ogle, C. W., et al. 295

Marks, D. F., see Beautrais, A. L. 37

Martin, A., see Waser, P. G., et al. 249

Mehraein, P., see Laschka, E., et al. 141

Mendlewicz, J., see Levitt, M., et al. 205

Mirsky, A. F., see Otero, J. B. 1

Mixich, G., see Jahn, U. 191

Moore, J. A., see Kakihana, R. 301

Morselli, P. L., Placidi, G. F., Maggini, C., Gomeni, R., Guazelli, M., de Lisio, G., Standen, S., Tognoni, G.
An Integrated Approach for the Evaluation of Psychotropic Drug in Man. I. Studies on Amphetamine. Relationship between Drug Levels and Psychophysiological Measurements 211

Niemegeers, C. J. E., see Colpaert, F. C., et al. 169

Niemegeers, C. J. E., see Wauquier, A. 179

Noble, E. P., Gillies, R., Vigran, R., Mandel, P.
The Modification of the Ethanol Withdrawal Syndrome in Rats by Di-*n*-propylacetate 127

Ogle, C. W., Turner, P., Markomihelakis, H.
The Effects of High Doses of Oxprenolol and of Propranolol on Pursuit Rotor Performance, Reaction Time and Critical Flicker Frequency 295

Otero, J. B., Mirsky, A. F.
Influence of Secobarbital and Chlorpromazine on Precentral Neuron Activity during Attentive Behavior in Monkeys 1

Papeschi, R., Theiss, P., Ayhan, H.
AMT Catalepsy and Hypokinesia: Interaction with Morphine and Cocaine 149

Paschelke, G., see Bläsig, J., et al. 41

Pasternak, V., see Bergmann, F., et al. 87

Picchioni, A. L., see Ageel, A. M., et al. 311

Placidi, G. F., see Morselli, P. L., et al. 211

Popping, A., see Rigter, H. 255

Quattrone, A., see Samanin, R., et al. 219

Richter, N. A., see Gerald, M. C. 277

Riege, W. H., Cherkin, A.
Memory Performance after Flurothyl Treatment in Rainbow Trout 31

Rigter, H., Popping, A.
Hormonal Influences on the Extinction of Conditioned Taste Aversion 255

Ruch, W., Asper, H., Bürki, H. R.
Effect of Clozapine on the Metabolism of Serotonin in Rat Brain 103

Samanin, R., Bernasconi, S., Quattrone, A.
Antinociceptive Action of Quipazine: Relation to Central Serotonergic Receptor Stimulation 219

Sanders, B., Collins, A. C., Wesley, V. H.
Reduction of Alcohol Selection by Pargyline in Mice 159

Schreiber, H. L., Gibson Wood, W., Carlson, R. H.
Tolerance in Methylphenidate-Induced Locomotion in Prairie Dogs *(Cynomys ludovicianus)* 111

Seiler, N., see Korr, H. 53

Sell, A. B., see Fonseca, N. M., et al. 263

Senault, B.
Amantadine: Effet agressogène propre; Effet sur l'agressivité induite par l'apomorphine chez le rat 167

Shagass, C., see Straumanis, J. J., Jr. 283

Singer, G., see Stanes, M. D., et al. 269

Stallone, F., see Levitt, M., et al. 205

Standen, S., see Morselli, P. L., et al. 211

Stanes, M. D., Brown, C. P., Singer, G.
Effect of Physostigmine on Y-maze Discrimination Retention in the Rat 269

Starmer, G. A., see Welburn, P. J., et al. 83

Stock, G., Heinemann, H., Bergande, F.
Changes in Exitability of Amygdaloid and Septal Nuclei Induced by Medazepam Hydrochloride 197

Straumanis, Jr., J. J., Shagass, C.
Electrophysiological Effects of Triiodothyronine and Propranolol 283

Suzuki, J. S., see Bueno, O. F. A., et al. 235

Teschemacher, Hj., see Laschka, E., et al. 141

Tetsche, K., Fjerdingstad, E. J., Fjerdingstad, E.
Euflavine: Effect on Brain Heavy Metal Content and Staining Pattern, and on Shuttle Box Behavior in Goldfish 123

Theiss, P., see Papeschi, R., et al. 149

Tikal, K., Benešová, O., Fraňková
The Effect of Pyrithioxine and Pyridoxine on Individual Behavior, Social Interactions, and Learning in Rats Malnourished in Early Postnatal Life 325

Tognoni, G., see Morselli, P. L., et al. 211

Trafton, C. L., see Ageel, A. M., et al., 311

Ts'o, T. O. T., Hance, A. J., Killam, K. F.
Performance Enhancement Effects of *d*-Amphetamine, Methylphenidate, Pipradol and Phenindamine in Rats 65

Turner, P., see Ogle, C. W., et al. 295

Vigran, R., see Noble, E. P., et al. 127

Vospalek, D. M., see Jones, C. N., et al. 59

Waser, P. G., Martin, A., Heer-Carcano, L.
The Effect of Δ^9-Tetrahydrocannabinol and LSD on the Acquisition of an Active Avoidance Response in the Rat 249

Wauquier, A., Niemegeers, C. J. E.
Intracranial Self-Stimulation in Rats as a Function of Various Stimulus Parameters. VI. Influence of Fentanyl, Piritramide, and Morphine on Medial Forebrain Bundle Stimulation with Monopolar Electrodes 179

Welburn, P. J., Starmer, G. A., Chesher, G. B., Jackson, D. M.
Effects of Cannabinoids on the Abdorminal Constriction Response in Mice: Within Cannabinoid Interactions 83

Wesley, V. H., see Sanders, B., et al. 159

de Wied, D., Gispen, W. H.
Impaired Development of Tolerance to Morphine Analgesia in Rats with Hereditary Diabetes Insipidus 27

Wood, W. G., see Schreiber, H. L., et al. 111

Yanai, J., Ginsburg, B. E.
Increased Sensitivity to Chronic Ethanol in Isolated Mice 185

Indexed in Current Contents

Subject Index

A

Abdominal constriction response 83
Acetylator status 289
Acquisition 311
ACTH-analogues 255
Activity 163
Acute and chronic effects 11
Adrenalectomy 317
Affective illness 205
Alcohol 163, 301
—, preference 163
—, selection 159
Alpha-methyl-p-tyrosine 149
γ-Aminobutyric acid 127
Amnesia reversal 31
Amphetamine 73, 169, 211, 223, 235, 263, 307
—, stereotypies 317
d-Amphetamine 19, 59, 65
Amyqdala 197
Antipressant effect 289
Antihistamines 277
Antinociception 83, 219
Arousal 73
Arterial pressure 197
Atropine 73
Attention 1
Audiogenic seizures 127
Autoradiography 53, 115
Avoidance 119
—, learning 325
—, memory 31
—, response 249, 311

B

Barbiturates 263
Behavioral activity 73
—, toxicity 65
Benzylideneaminooxycarbonic acids 191
Beta-adrenoceptor blockade 295
Blood levels 211
—, pressure 211
Brain
—, catecholamines 149
—, distribution pattern 53, 115
—, rat 103
Brocresine 277
Butyrophenones 263

C

Cannabinoid interactions 83
Cannabis 37
Carbon dioxide 31
Catalepsy 149
Catatonia 179
Cats 197, 229
4-Chloramphetamine 11
Chlordiazepoxide 169
p-Chlorophenylalanine 87
Chlorpromazine 1, 263, 311
Circadian rythm 301
Clozapine 103
CNS effects 211
—, function tests 295
Cocaine 149, 229
Conditioning 245
Corticosterone 301
Cue 169

D

Depression 19
—, spreading 93
Desipramine 169
Diabetes insipidus 27
Diazepam 263
Di-*n*-propylacetate 127
Discrimination learning 59
Discriminative stimulus 65
Dopamine 11
Dose-level 269
Drug
—, discrimination 169, 235
—, dependence 191
—, generalization 235

E

Early treatments 263
EEG 283
Encephabol 325
Ethanol 235
—, consumption 185
—, withdrawal 127
Exercise 205
Extinction 255
—, procedure 119

F

Fentanyl 179
Flurothyl 31
Functional pool 149

G

Genetics 205
Gnawing, compulsive 87

H

H_1 and H_2 receptor antagonists 277
Haloperidol 169
Hippocampal EEG 73
Hippocampus 115
Histaminergic system 277
Human subjects 37, 205, 211, 283, 289, 295
5-Hydroxy-indoleacetic acid 11
Hypokinesia 149

I

Intraventricular injection 141
Isolation 185

L

—, ability 269
LSD 249
Learning 93, 269

M

Malnutrition 325
MAOI 317
Marmoset 115
Maze learning 263
Mecamylamine 119
Medazepam hydrochloride 197
Medial forebrain bundle 179
Memory 93, 269
—, enhancement 31
Mescaline 115
Mescaline isomer 2,3,4-TMPEA 53
Methamphetamine 229
Methergoline 219
Methylphenidate 65, 111
Metiamide 277
Mice 53, 83, 159, 277, 301
—, inbred 185
Microinjection 141
Midbrain raphe lesions 219
MIF 255
Monkeys 1
Monoamine oxidase inhibitors 289
—, turnover in brain 11
Morphine 87, 149, 179, 223, 245, 311
—, antagonists 41, 141
—, dependence 133
—, partial antagonists 41
—, tolerance 27
—, withdrawal precipitated 41, 133, 141
Motor activity 111
MSH 255
Multiple schedule 65

N

Narcotic antagonists 223
Neuroleptic drugs 103
Neurons, precentral 1
Nicotine 119
Noradrenaline 11

O

Offspring behavior 163
Open-field behavior 263, 325

Operant behavior 307
Opiate binding, stereospecific 41

P

Parachlorophenylalanine 159
Pargyline 159
Pattern discrimination 93
Pentylene tetrazol seizures 277
Performance 211
—, enhancement 65
Phenelzine excretion 289
Phenindamine 65
Photically evoked after-discharge 73
Physostigmine 73, 269
Pilocarpine 73
Pipradrol 65
Piritramide 179
Plasma DBH activity 205
Prairie dogs 111
Pregnancy 163
Propranolol 283
Psychomotor behavior 197
—, performance 37
Pyridoxine 325
Pyrithioxine 325

Q

Quasi-abstinence 191
Quipazine 219

R

Rainbow trout 31
Rate dependency 307
Rats 11, 19, 27, 41, 59, 65, 73, 87, 93, 103, 119, 127, 133, 141, 149, 163, 169, 179, 191, 219, 223, 235, 245, 249, 255, 263, 269, 307, 311, 317, 325
Relationships 211
RHA 119

S

Secobarbital 1
Self administration 229
—, stimulation 19, 179, 223
Sensitivity to chronic ethanol 185
Septum
Serotonin 11, 103, 159, 219
Sgd 8473 191
Side effects 289
Sites of action 133, 141
Social interaction 325
Somatosensory evoked potential 283
State dependent 37
—, learning 169, 249
Stimulus parameter combinations 179
—, properties of drugs 59

T

Taste aversion, conditioned 255
Tetrahydrocannabinol 235
—, Δ^9 249
Tolerance 19, 111, 249
Triiodothyronine 283
Tryptophan 103

V

Vasopressin 27

W

"Wet dog shake", chemically induced 191
Withdrawal 245, 249
—, precipitated 41, 133, 141

Recent Publications in the NEUROSCIENCES

THE USE OF AXONAL TRANSPORT FOR STUDIES OF NEURONAL CONNECTIVITY

edited by **W. MAXWELL COWAN** *and* **MICHEL CUĔNOD.**

1975. 368 pages. US $ 40.95/Dfl. 98.00. ISBN 0-444-41347-2

Methods of tracing neuronal pathways based on the intra-axonal transport of isotopically labeled proteins and other cytochemically demonstrable markers have met with great success. In view of this rapid progress, a symposium was organized for the debate and development of this technique, and following the symposium, a selection of the speakers were asked to submit written copies of their presentations. The resulting volume, which was strictly edited to prevent an overlapping of material, will serve all workers in the important areas of neurophysiology, neuroanatomy, physiological psychology, neurochemistry and neuroembryology.

NEURAL AND ENDOCRINE ASPECTS OF BEHAVIOUR IN BIRDS

edited by **PETER WRIGHT, PETER G. CARYL** *and* **DAVID M. VOWLES.**

1975. 420 pages. US $ 40.95/Dfl. 98.00. ISBN 0-444-41356-1

Research on avian behaviour has been heavily influenced by ethological ideas and techniques, and this book illustrates the synthesis which has recently been achieved between this approach and the more orthodox psychological and neurophysiological studies of the relationship between brain and behaviour. Although the chapters all report work dealing specifically with birds, several authors have made comparisons with relevant mammalian studies, and as a result the book is useful to the general reader interested in brain-behaviour relationships.

HORMONES, HOMEOSTASIS AND THE BRAIN

Proceedings of the Vth International Congress of the International Society of Psychoneuroendocrinology.

edited by **W.H. GISPEN, Tj. B. VAN WIMERSMA GREIDANUS, B. BOHUS** *and* **D. DE WIED.**

PROGRESS IN BRAIN RESEARCH, Vol. 42

1975. 402 pages. US $ 60.50/Dfl. 145.00. ISBN 0-444-41292-1

The major themes of this proceedings volume, comprising some forty papers, are: effects of hypothalamic releasing factors on the CNS; hormones and sleep; hormonal influences on learning and memory functions; central regulation of homeostasis, and early hormonal influences on ontogenesis of behaviour and brain development.

FUNCTIONS OF THE NERVOUS SYSTEM

Vol. 1: General Physiology/Autonomic Functions

by **MARCEL MONNIER.**

1968. 695 pages. US $ 62.50/Dfl. 150.00. ISBN 0-444-40689-1

"...there is no comparable book containing so much of the type of information a neurologist or clinical neurophysiologist... requires to have available for reference."
Journal of Neurology, Neurosurgery and Psychiatry

Vol. 2: Motor and Psychomotor Functions

by **MARCEL MONNIER** *with a contribution by* R. Tissot.

1970. 676 pages. US $ 70.95/Dfl. 170.00. ISBN 0-444-40690-5

"...an ideal textbook for those who need the basic knowledge of the physiology of the motor system."
American Journal of Physical Medicine

Vol. 3: Sensory Functions and Perception

by **MARCEL MONNIER** *with contributions by* M. Fallert, M. Meulders *and* R. Tissot.

1975. 1000 pages. US $ 114.75/Dfl. 275.00.
ISBN 0-444-41231-X

This volume presents a well-planned and comprehensive overview of sensory functions and perception and is divided into four parts: general sensory physiology; special sensory physiology - somaesthesia; special senses; and the sense of vision.

ANATOMY OF THE CENTRAL NERVOUS SYSTEM IN REVIEW

by **DONALD H. FORD.**

1975. 230 pages. US $ 19.95/Dfl. 47.50. ISBN 0-444-41025-2

This timely review provides both an outline and a pictorial (or schematic) survey of those aspects of the central nervous system which seem relevant to comprehending the basic function of the nervous system as a whole. The major aspects of embryological development, gross structural divisions, internal and external support, vascular-ventricular systems and sensory and motor tract systems are covered in depth.

ELSEVIER SCIENTIFIC PUBLISHING COMPANY

P.O. Box 211, Amsterdam, The Netherlands

Distributed in the U.S.A. and Canada by:
AMERICAN ELSEVIER PUBLISHING COMPANY, INC.
52 Vanderbilt Ave., New York, N.Y. 10017

Prices are subject to change without prior notice.

1721E

HALOPERIDOL
HALOPERIDOL
HALOPERDOL
HALDEDOL

HALDOL
JANSSEN

© Janssen GmbH Düsseldorf
Hal./4.76
*Trade Mark

EIN NEUER NAME
FÜR EIN ALTBEWÄHRTES
PRODUKT.

Indikationen: Psychomotorische Erregungszustände; Unruhe bei Alterspatienten mit Zerebralsklerose; akute schizophrene Schübe und Manien; chronische schizophrene und maniforme Zustände; Alkoholismus; Entzugssymptome der Rausch- und Suchtdrogen; Hyperkinesen, Tic nerveux, Stottern, Chorea, Tourette-Syndrom; zentrales Erbrechen; medikamentöse Geburtserleichterung; Angst, Unruhe, Schmerzen. **Kontraindikationen:** Akute Alkohol-, Schlafmittel-, Analgetika- und Psychopharmaka-Intoxikationen. **Hinweise:** Bei nachgewiesener Stammhirnerkrankung sollte nach Verschlechterung der Symptome die Haldol-Janssen® Therapie abgesetzt werden. Bei allen depressiven Zustandsbildern, Parkinson-Syndrom, gleichzeitiger Gabe von Opiaten und/oder Barbituraten (Atemdepression) ist Vorsicht geboten. Bei Epileptikern darf die antiepileptische Behandlung nicht unterbrochen werden. Kindern sollte wegen erhöhter Empfindlichkeit des extrapyramidalen Systems Haldol-Janssen® nur in sehr geringen Dosen und einschleichend gegeben werden. Haldol-Janssen® kann bei bestimmungsmäßigem Gebrauch das Reaktionsvermögen so weit beeinträchtigen, daß es für den Straßenverkehr oder zur Bedienung von Kraftfahrzeugen oder Maschinen nicht mehr ausreicht; dies gilt in verstärktem Maße im Zusammenhang mit Alkoholgenuß. Wie bei jeder Medikation sollten während der Schwangerschaft die Vorteile einer Haldol-Janssen®-Behandlung gegen die Risiken einer Medikation sorgfältig abgewogen werden. Bei Patienten mit überstandenem Herzinfarkt sollte wegen der Antikoagulantientherapie stets nur i.v. oder oral und nicht i.m. appliziert werden. **Körperliche Begleitschäden:** Wie bei allen Neuroleptika können gelegentlich auch bei Haldol-Janssen® infolge Überdosierung oder besonderer Reaktionsbereitschaft parkinsonähnliche Symptome oder dyskinetische Reaktionen auftreten. Diese Symptome sind durch Dosisreduzierung oder Gabe von Antiparkinsonmitteln voll reversibel. **Zusammensetzung:** Haldol-Janssen®: 1 Tablette enthält 1 mg Haloperidol. 1 ml (= 20 Tropfen) oraler Tropflösung enthält 2 mg Haloperidol. 1 ml Injektionslösung enthält 5 mg Haloperidol. Haldol-Janssen® 0,5 mg: 1 Kapsel enthält 0,5 mg Haloperidol. **Handelsformen und Preise:** AVP incl. USt. (Stand: 4.76). Haldol-Janssen®: Originalpackungen, 75 Tabletten DM 27,80, 30 ml Tropfflasche DM 24,10, 100 ml Tropfflasche DM 67,90, 5 Ampullen mit 1 ml DM 13,35; Klinikpackungen, Tabletten, 30 ml Tropfflaschen, 100 ml Tropfflaschen, Ampullen mit 1 ml. Haldol-Janssen 0,5 mg: Originalpackung, 40 Kapseln DM 11,40.

JANSSEN GmbH DÜSSELDORF
Leopoldstr. 16 · Postfach 320560 · 4000 Düsseldorf 30 · Tel. (0211) 359031